These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 17868931

  • 21. BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys.
    Samadi P, Morissette M, Lévesque D, Di Paolo T.
    Mov Disord; 2010 Jan 15; 25(1):116-21. PubMed ID: 20014115
    [Abstract] [Full Text] [Related]

  • 22. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
    Grégoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T.
    Parkinsonism Relat Disord; 2013 May 15; 19(5):508-14. PubMed ID: 23402994
    [Abstract] [Full Text] [Related]

  • 23. Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain.
    Riahi G, Morissette M, Lévesque D, Rouillard C, Samadi P, Parent M, Di Paolo T.
    Neurochem Int; 2012 Dec 15; 61(7):1160-71. PubMed ID: 22940695
    [Abstract] [Full Text] [Related]

  • 24. Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus.
    Moroni F, Cozzi A, Carpendo R, Cipriani G, Veneroni O, Izzo E.
    Neuropharmacology; 2005 May 15; 48(6):788-95. PubMed ID: 15829251
    [Abstract] [Full Text] [Related]

  • 25. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar 15; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 26. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Papa SM, Chase TN.
    Ann Neurol; 1996 May 15; 39(5):574-8. PubMed ID: 8619541
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
    Bourque M, Grégoire L, Di Paolo T.
    Behav Brain Res; 2018 Jan 30; 337():183-185. PubMed ID: 28917506
    [Abstract] [Full Text] [Related]

  • 29. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
    Hadj Tahar A, Grégoire L, Darré A, Bélanger N, Meltzer L, Bédard PJ.
    Neurobiol Dis; 2004 Mar 30; 15(2):171-6. PubMed ID: 15006686
    [Abstract] [Full Text] [Related]

  • 30. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb 30; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 31. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    Mov Disord; 1998 Sep 30; 13(5):798-802. PubMed ID: 9756148
    [Abstract] [Full Text] [Related]

  • 32. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.
    Ouattara B, Grégoire L, Morissette M, Gasparini F, Vranesic I, Bilbe G, Johns DR, Rajput A, Hornykiewicz O, Rajput AH, Gomez-Mancilla B, Di Paolo T.
    Neurobiol Aging; 2011 Jul 30; 32(7):1286-95. PubMed ID: 20036444
    [Abstract] [Full Text] [Related]

  • 33. The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys.
    Samadi P, Grégoire L, Bédard PJ.
    Neurobiol Dis; 2004 Jun 30; 16(1):246-53. PubMed ID: 15207281
    [Abstract] [Full Text] [Related]

  • 34. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys.
    Hadj Tahar A, Grégoire L, Bangassoro E, Bédard PJ.
    Clin Neuropharmacol; 2000 Jun 30; 23(4):195-202. PubMed ID: 11020123
    [Abstract] [Full Text] [Related]

  • 35. Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
    Konitsiotis S, Tsironis C.
    Behav Brain Res; 2006 Jun 30; 170(2):337-41. PubMed ID: 16621050
    [Abstract] [Full Text] [Related]

  • 36. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M.
    Neuroscience; 2005 Jun 30; 132(2):409-20. PubMed ID: 15802193
    [Abstract] [Full Text] [Related]

  • 37. AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
    Bourque M, Grégoire L, Patel W, Dickens D, Snodgrass R, Di Paolo T.
    Cells; 2022 Nov 08; 11(22):. PubMed ID: 36428960
    [Abstract] [Full Text] [Related]

  • 38. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N, Martín AB, Mendialdua A, Moratalla R.
    Biol Psychiatry; 2006 Jan 01; 59(1):64-74. PubMed ID: 16139809
    [Abstract] [Full Text] [Related]

  • 39. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
    Morin N, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T.
    Neuropharmacology; 2010 Jun 01; 58(7):981-6. PubMed ID: 20074579
    [Abstract] [Full Text] [Related]

  • 40. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
    Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R.
    Exp Neurol; 2006 Jan 01; 197(1):31-40. PubMed ID: 16099455
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.